Clinical trials: TNF-alpha Inhibitors
Rheumatoid Arthritis
RHYTHM (Formerly Escape II Myocardium)
For aim 1, the proposed studies will be performed in 150 patients with RA and 25 subjects without RA (healthy volunteers) who will function as controls.
- Trial name
- RHYTHM (NCT01548768)
- Testing
- TNF inhibitors, DMARDs
- Where
- United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Columbia University
Colitis,Ulcerative
Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?
The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the option to restart treatment in the case of…
- Trial name
- BIOSTOP (NCT03011268)
- Testing
- Discontinuation of anti-TNF treatment, Continuation of anti-TNF treatment
- Where
- 19 sites in Norway
- Volunteers
- 174 people
- Sponsor
- Helse Møre og Romsdal HF
Inflammatory Bowel Diseases, Crohn Disease
Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with inflammatory bowel disease (IBD) in Saudi Arabia where no visits or intervention(s) additional to the…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Fistulizing Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT03452501
- Testing
- Infliximab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 157 people
- Sponsor
- Hikma Pharmaceuticals LLC
Rheumatoid Arthritis
Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis
Background: Rheumatoid arthritis (RA) is often treated with drugs known as tumor necrosis factor (TNF) inhibitors, that can help decrease joint pain and swelling and can even result in RA remission.
- Trial name
- STARA (NCT01793519)
- Testing
- Etanercept, Infliximab, Adalimumab
- Where
- 2 sites in United States
- Volunteers
- 290 people
- Sponsor
- Georgetown University
Rheumatoid Arthritis
Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with rheumatoid arthritis(RA) in Jordan where no visits or intervention(s) additional to the daily practice…
- Trial name
- PASSRRA (NCT03348046)
- Testing
- Biosimilar Infliximab
- Where
- 2 sites in Jordan
- Volunteers
- 22 people
- Sponsor
- Hikma Pharmaceuticals LLC
Dental Implants, TNF-alpha Inhibitors
Dental Implant Healing With TNF-Alpha Inhibitors
The goal of this pilot study is to learn about healing after dental implant placement in patients taking a class of biologic drug called Tumor Necrosis Factor or TNF-alpha antagonist or inhibitor.
- Conditions
- Dental Implants, TNF-alpha Inhibitors, Edentulism
- Trial name
- NCT06538870
- Testing
- Placement of dental implants
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Neutropenia, TNF-alpha Inhibitors
Neutropenia With TNF-α Inhibitors
Tumor necrosis factor-alpha (TNF-α) inhibitors, including infliximab, etanercept, adalimumab, certolizumab, and golimumab, have become cornerstone therapies in the management of rheumatologic disorders.
- Trial name
- NCT07237906
- Where
- Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Burak Ugur Cetin
Rheumatoid Arthritis
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding…
- Trial name
- NCT03001219
- Testing
- Anti-TNF-alpha, Methotrexate, RO7123520
- Where
- 81 sites in United States, Argentina and 9 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Inflammatory Bowel Disease (IBD), Spondylarthropathies
Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital
Prevelance of axial spondylosis arthritis in inflammatory bowel disease and its RESPONSE to tumour necrosis factor (TNF) inhibitors TREATMENT
- Conditions
- Inflammatory Bowel Disease (IBD), Spondylarthropathies, TNF-alpha Inhibitors
- Trial name
- NCT06601595
- Testing
- TNF inhibitors, conventional ibd medical treatment
- Volunteers
- 100 people
- Sponsor
- Mohamed Nasr
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Ankylosing Spondylitis
An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)
Due to the rigor of the clinical development program of adalimumab for the indication of AS, the population of subjects with active AS that could enroll in previous phase 3 studies was limited.
- Trial name
- RHAPSODY (NCT00478660)
- Testing
- adalimumab (Humira)
- Where
- 205 sites in Austria, Belgium and 13 more
- Volunteers
- 1,250 people
- Sponsor
- Abbott
Perioperative Inflammatory Response
Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery
The purpose of the present study is to quantify the degree of modulation, if any, in the perioperative inflammatory response associated with statins use.
- Trial name
- NCT00656292
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Mayo Clinic
SPONDYLOARTHRITIS
Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis
Spondylarthropathy (SpA) comprises a group of rheumatic diseases mainly affecting the spine and sacroiliac joints. In most of the patients disease activity alternates, and some patients have symptom free periods.
- Trial name
- SPARTA (NCT00726804)
- Testing
- Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
- Where
- 6 sites in Denmark
- Volunteers
- 7 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Hand Osteoarthritis
Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis
Digital osteoarthritis (DO) which affects the interphalangeal joints and the Metacarpophalangeal (MCP) of the thumb is a common disease, the prevalence of which increases with age (36% of the population aged over 70).
- Trial name
- DORA (NCT00597623)
- Testing
- Adalimumab (Humira®)
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ulcerative Colitis, Crohn's Disease
A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn's Disease (CD). This is happening because people are living longer and because more people overall are developing UC or…
- Trial name
- NCT07250815
- Testing
- No intervention
- Where
- United States
- Sponsor
- Takeda
Ulcerative Colitis
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT03760003
- Testing
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg
- Where
- 130 sites in United States, Austria and 15 more
- Volunteers
- 355 people
- Sponsor
- Abivax S.A.
Primary IgA Nephropathy
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world.There is to date no curative therapy for patients with IgAN.It is considered that dendritic cells, Toll-like receptor (TLR) 9 and…
- Trial name
- HCQIgAN (NCT02765594)
- Testing
- Hydroxychloroquine Sulfate, Valsartan
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
RheumatoId Arthritis
French National Registry: ART REGISTRY (Observational Study)
Rheumatoid arthritis (RA) is a complex and multifactorial autoimmune disease. The biological treatments that are currently available for the treatment of RA are the TNF-alpha inhibitors.
- Trial name
- ART (NCT03062865)
- Testing
- No intervention
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris